Re-Aim Therapeutics
PrivateLast Round
Seed
May 18, 2026
Total Funding Raised
$9.4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Re-Aim Therapeutics is a biotechnology company that develops targeted biologics to treat autoimmune diseases by selectively depleting pathogenic T cell subsets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Re-Aim Therapeutics Comparables
Compare Re-Aim Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hillstar Bio | 85% | |
| Elemental Biologics | 85% | |
| Abcuro | 76% |
Re-Aim Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 18, 2026 |
Re-Aim Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Syncona | Seed |
| Oxford Science Enterprises | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 18, 2026
$9.4M round led by Oxford Science Enterprises and Syncona.
Re-Aim Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Re-Aim Therapeutics's valuation, stock price, and market status.
Is Re-Aim Therapeutics a public or private company?
Re-Aim Therapeutics is a private company.
What is the current stock price of Re-Aim Therapeutics?
Re-Aim Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Re-Aim Therapeutics worth (valuation)?
Valuation information for Re-Aim Therapeutics is not publicly available.
Can I buy Re-Aim Therapeutics stock?
Re-Aim Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Re-Aim Therapeutics's last funding round?
Re-Aim Therapeutics's most recent funding round was Seed on May 18, 2026.
Who are the main investors in Re-Aim Therapeutics?
Key investors in Re-Aim Therapeutics include Syncona, Oxford Science Enterprises.
Will Re-Aim Therapeutics IPO soon?
No public IPO plans have been announced for Re-Aim Therapeutics.
How can I track Re-Aim Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Re-Aim Therapeutics's secondary market activity and sign up for updates.